Pluri Inc. (PluriStem Therapeutics Inc.) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 23, 2008, by PluriStem Therapeutics Inc., a Nevada corporation. The report discloses a material definitive agreement entered into on September 22, 2008, involving the sale of equity securities to an investor.
Key Financial Metrics and Transaction Details
The filing details a specific capital raise transaction rather than periodic financial performance metrics. Key terms of the transaction include:
- Shares Sold: 900,000 shares of Common Stock.
- Warrants Issued: Warrants to purchase 675,000 shares of Common Stock.
- Price per Share: $1.15 for Common Stock.
- Warrant Exercise Price: $1.90 per share.
- Warrant Term: Five years.
- Registration: The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-151761).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transaction-specific report.
Material Changes
The primary material change is the increase in outstanding share count and the creation of new warrant obligations resulting from the September 22, 2008 securities purchase agreement. No other material changes to operations or financial condition are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure that the description of the Warrants is a summary qualified by reference to the full legal text in Exhibit 4.1. The transaction was executed under Rule 424(b) with a prospectus supplement filed with the SEC.
Key Facts for Investor Verification
- Verify the total gross proceeds from the sale of 900,000 shares at $1.15 per share.
- Confirm the dilution impact of the 900,000 new shares and the potential 675,000 shares from warrant exercises.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or registration rights.
- Check the Form S-3 shelf registration status to ensure the offering was properly authorized.
- Assess the company's cash position post-transaction to determine runway for operations.